Genetic plasma biomarkers associated with ischemic stroke

Abstract

Aim:Stroke is one of the leading causes of death and disability worldwide. Plasma biomarkers have long been used to evaluate physiological or pathological processes and to make predictions about the outcome of stroke patients. The current systematic review is focused on genetic plasma biomarkers as a new potential prognostic indicator for post-stroke recovery. The aim of the present systematic review is to assess the potential of genetic plasma biomarkers associated with stroke to predict post-stroke recovery.

Methods:The search strategy used PubMed and Web of Science databases to identified 166 studies that investigated genetic plasma biomarkers in patients with stroke between 2017 and 2021. However, only 21 of them met the inclusion criteria.

Results:The identified genetic biomarkers can be divided into: (i) serum/plasma circular RNA (circRNA) associated with stroke onset or recurrence (5; 23.80%), (ii) genetic polymorphisms associated with the atherosclerotic process and stroke recurrence (6; 28.57%), (iii) serum/plasma long non-coding RNA (lncRNA) levels involved in immunity/inflammatory processes (4; 19.04%), (iv) marker of DNA methylation associated with stroke onset and outcome (3; 14.28%), and (v) proteins and pathways of stroke identified by serum/ plasma proteomics/genomics analysis (3; 14.28%).

Conclusions:Overall, more than 100 potential biomarkers were found and the data suggest that combinations of plasma genetic biomarkers might be used as a better predictor for stroke.

Keywords

Ischemic stroke / RNA / DNA / methylation

References

[1] Wilkins EWilson LWickramasinghe KBhatnagar PLeal JLuengo-Fernandez Ret al. European cardiovascular disease statistics 2017. Brussels: European Heart Network; 2017.

[2] Benjamin EJVirani SSCallaway CWChamberlain AMChang ARCheng Set al.American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–492. Erratum in: Circulation. 2018;137:e493.

[3] Feigin VLNorrving BMensah GA. Global burden of stroke. Circ Res. 2017;120:439–48.

[4] Virani SSAlonso AAparicio HJBenjamin EJBittencourt MSCallaway CWet al.American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143:e254–743.

[5] Langhorne PCoupar FPollock A. Motor recovery after stroke: a systematic review. Lancet Neurol. 2009;8:741–54.

[6] O’Collins VEMacleod MRDonnan GAHorky LLvan der Worp BHHowells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467–77.

[7] Ni JQu JYao MZhang ZZhong XCui LRESK investigators. Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): protocol for an open-label, single-arm, multicenter phase IV trial for the treatment of acute ischemic stroke in Chinese patients. Transl Stroke Res. 2017;8:341–6.

[8] Dong YQu JZhang ZWang CDong Q. Human urinary kallidinogenase in treating acute ischemic stroke patients: analyses of pooled data from a randomized double-blind placebo-controlled phase IIb and phase III clinical trial. Neurol Res. 2020;42:286–90.

[9] Enomoto MEndo AYatsushige HFushimi KOtomo Y. Clinical effects of early edaravone use in acute ischemic stroke patients treated by endovascular reperfusion therapy. Stroke. 2019;50:652–8.

[10] Hill MDGoyal MMenon BKNogueira RGMcTaggart RADemchuk AMet al.ESCAPE-NA1 Investigators. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020;395:878–87.

[11] Lyden PPryor KECoffey CSCudkowicz MConwit RJadhav Aet al.NeuroNEXT Clinical Trials Network NN104 Investigators. Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. Ann Neurol. 2019;85:125–36.

[12] Driga MPCatalin BOlaru DGSlowik APlesnila NHermann DMet al. The need for new biomarkers to assist with stroke prevention and prediction of post-stroke therapy based on plasma-derived extracellular vesicles. Biomedicines. 2021;9:1226.

[13] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.

[14] Montellano FAUngethüm KRamiro LNacu AHellwig SFluri Fet al. Role of blood-based biomarkers in ischemic stroke prognosis: a systematic review. Stroke. 2021;52:543–51. Erratum in: Stroke. 2021;52:e106.

[15] Lai YJHanneman SKCasarez RLWang JMcCullough LD. Blood biomarkers for physical recovery in ischemic stroke: a systematic review. Am J Transl Res. 2019;11:4603–13.

[16] Whiteley WChong WLSengupta ASandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009;40:e380–9.

[17] Liberati AAltman DGTetzlaff JMulrow CGøtzsche PCIoannidis JPet al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

[18] Silva PWM Shimon SMde Brito LMReis-das-Mercês LMagalhães LAraújo Get al. Novel insights toward human stroke-related epigenetics: circular RNA and its impact in poststroke processes. Epigenomics. 2020;12:1957–68.

[19] Patop ILWüst SKadener S. Past, present, and future of circRNAs. EMBO J. 2019;38:e100836.

[20] Lu DHo ESMai HZang JLiu YLi Yet al. Identification of blood circular RNAs as potential biomarkers for acute ischemic stroke. Front Neurosci. 2020;14:81.

[21] Brushia RJWalsh DA. Phosphorylase kinase: the complexity of its regulation is reflected in the complexity of its structure. Front Biosci. 1999;4:D618–41.

[22] Nachury MVLoktev AVZhang QWestlake CJPeränen JMerdes Aet al. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. Cell. 2007;129:1201–13.

[23] Ostolaza ABlanco-Luquin IUrdánoz-Casado ARubio ILabarga AZandio Bet al. Circular RNA expression profile in blood according to ischemic stroke etiology. Cell Biosci. 2020;10:34.

[24] Abe ATanaka MYasuoka ASaito YOkada SMishina Met al. Changes in whole-blood microRNA profiles during the onset and treatment process of cerebral infarction: a human study. Int J Mol Sci. 2020;21:3107.

[25] Jickling GCAnder BPZhan XNoblett DStamova BLiu D. microRNA expression in peripheral blood cells following acute ischemic stroke and their predicted gene targets. PLoS One. 2014;9:e99283.

[26] Vijayan MKumar SYin XZafer DChanana VCengiz Pet al. Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke. Hum Mol Genet. 2018;27:2318–29.

[27] Dhiraj DKChrysanthou EMallucci GRBushell M. miRNAs-19b, -29b-2* and -339-5p show an early and sustained up-regulation in ischemic models of stroke. PLoS One. 2013;8:e83717.

[28] Mick EShah RTanriverdi KMurthy VGerstein MRozowsky Jet al. Stroke and circulating extracellular RNAs. Stroke. 2017;48:828–34.

[29] Zhu WTian LYue XLiu JFu YYan Y. LncRNA expression profiling of ischemic stroke during the transition from the acute to subacute stage. Front Neurol. 2019;10:36.

[30] Zhou LXu DYSha WGShen LLu GY. Long non-coding RNA MALAT1 interacts with transcription factor Foxo1 to regulate SIRT1 transcription in high glucose-induced HK-2 cells injury. Biochem Biophys Res Commun. 2018;503:849–55.

[31] Cao YWang JLu XKong XBo CLi Set al. Construction of a long non-coding RNA-mediated transcription factor and gene regulatory triplet network reveals global patterns and biomarkers for ischemic stroke. Int J Mol Med. 2020;45:333–42.

[32] Kohn ADTakeuchi FRoth RA. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem. 1996;271:21920–6.

[33] Wang YFeng FZheng PWang LWang YLv Yet al. Dysregulated lncRNA and mRNA may promote the progression of ischemic stroke via immune and inflammatory pathways: results from RNA sequencing and bioinformatics analysis. Genes Genomics. 2022;44:97–108.

[34] Adams BDParsons CWalker LZhang WCSlack FJ. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127:761–71.

[35] Feng LGuo JAi F. Circulating long noncoding RNA ANRIL downregulation correlates with increased risk, higher disease severity and elevated pro-inflammatory cytokines in patients with acute ischemic stroke. J Clin Lab Anal. 2019;33:e22629.

[36] Deng QWLi SWang HSun HLZuo LGu ZTet al. Differential long noncoding RNA expressions in peripheral blood mononuclear cells for detection of acute ischemic stroke. Clin Sci (Lond). 2018;132:1597–614.

[37] Sheng YMa JZhao JQi SHu RYang Q. Differential expression patterns of specific long noncoding RNAs and competing endogenous RNA network in alopecia areata. J Cell Biochem. 2019;120:10737–47.

[38] Zhang LLiu BHan JWang THan L. Competing endogenous RNA network analysis for screening inflammation-related long non-coding RNAs for acute ischemic stroke. Mol Med Rep. 2020;22:3081–94.

[39] He WWei DCai DChen SLi SChen W. Altered long non-coding RNA transcriptomic profiles in ischemic stroke. Hum Gene Ther. 2018;29:719–32.

[40] Zhu RZhao YXiao TWang QLiu X. Association between microRNA binding site polymorphisms in immunoinflammatory genes and recurrence risk of ischemic stroke. Genomics. 2020;112:2241–6.

[41] Kajiho HSaito KTsujita KKontani KAraki YKurosu Het al. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J Cell Sci. 2003;116:4159–68.

[42] Chanson MKwak BR. Connexin37: a potential modifier gene of inflammatory disease. J Mol Med (Berl). 2007;85:787–95.

[43] Collings ARaitakari OTJuonala MMansikkaniemi KKähönen MHutri-Kähönen Net al. The influence of smoking and homocysteine on subclinical atherosclerosis is modified by the connexin37 C1019T polymorphism - the Cardiovascular Risk in Young Finns Study. Clin Chem Lab Med. 2008;46:1102–8.

[44] Li HYu SWang RSun ZZhou XZheng Let al. Polymorphism of CONNEXIN37 gene is a risk factor for ischemic stroke in Han Chinese population. Lipids Health Dis. 2018;17:72.

[45] Xie JQLu YPSun HLGao LNSong PPFeng ZJet al. Sex difference of ribosome in stroke-induced peripheral immunosuppression by integrated bioinformatics analysis. Biomed Res Int. 2020;2020:3650935.

[46] Zhou XMarks PARifkind RARichon VM. Cloning and characterization of a histone deacetylase, HDAC9. Proc Natl Acad Sci U S A. 2001;98:10572–7.

[47] Shroff NAnder BPZhan XStamova BLiu DHull Het al. HDAC9 polymorphism alters blood gene expression in patients with large vessel atherosclerotic stroke. Transl Stroke Res. 2019;10:19–25.

[48] Williams SRHsu FCKeene KLChen WMDzhivhuho GRowles JL3rdet al.GARNET (The Genomics and Randomized Trials Network) Collaborative Research Group. Genetic drivers of von Willebrand factor levels in an ischemic stroke population and association with risk for recurrent stroke. Stroke. 2017;48:1444–50.

[49] Davis Armstrong NMSpragley KJChen WMHsu FCBrewer MSHorn PJet al. Multi-omic analysis of stroke recurrence in African Americans from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial. PLoS One. 2021;16:e0247257.

[50] Chan SJNg MPEZhao HNg GJLDe Foo CWong PTet al. Early and sustained increases in leukotriene B4 levels are associated with poor clinical outcome in ischemic stroke patients. Neurotherapeutics. 2020;17:282–93.

[51] Davis Armstrong NMChen WMHsu FCBrewer MSCullell NFernández-Cadenas Iet al. DNA methylation analyses identify an intronic ZDHHC6 locus associated with time to recurrent stroke in the Vitamin Intervention for Stroke Prevention (VISP) clinical trial. PLoS One. 2021;16:e0254562.

[52] Bousette NAbbasi CChis RGramolini AO. Calnexin silencing in mouse neonatal cardiomyocytes induces Ca2+ cycling defects, ER stress, and apoptosis. J Cell Physiol. 2014;229:374–83.

[53] Portela AEsteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–68.

[54] Heyn HLi NFerreira HJMoran SPisano DGGomez Aet al. Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A. 2012;109:10522–7.

[55] Bollati VSchwartz JWright RLitonjua ATarantini LSuh Het al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. Mech Ageing Dev. 2009;130:234–9.

[56] Jones MJGoodman SJKobor MS. DNA methylation and healthy human aging. Aging Cell. 2015;14:924– 32.

[57] Hannum GGuinney JZhao LZhang LHughes GSadda Set al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49:359–67.

[58] Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:R115. Erratum in: Genome Biol. 2015;16:96.

[59] Soriano-Tárraga CGiralt-Steinhauer EMola-Caminal MOis ARodríguez-Campello ACuadrado-Godia Eet al. Biological age is a predictor of mortality in ischemic stroke. Sci Rep. 2018;8:4148.

[60] Chen BHMarioni REColicino EPeters MJWard-Caviness CKTsai PCet al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. Aging (Albany NY). 2016;8:1844–65.

[61] Marioni REShah SMcRae AFChen BHColicino EHarris SEet al. DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol. 2015;16:25.

[62] Shen RZhao XHe LDing YXu WLin Set al. Upregulation of RIN3 induces endosomal dysfunction in Alzheimer’s disease. Transl Neurodegener. 2020;9:26.

[63] Boden KABarber ISClement NPatel TGuetta-Baranes TBrookes KJet al.ARUK Consortium; Morgan K, Seymour GB, Bottley A. Methylation profiling RIN3 and MEF2C identifies epigenetic marks associated with sporadic early onset Alzheimer’s disease. J Alzheimers Dis Rep. 2017;1:97–108.

[64] Miao MYuan FMa XYang HGao XZhu Zet al. Methylation of the RIN3 promoter is associated with transient ischemic stroke/mild ischemic stroke with early cognitive impairment. Neuropsychiatr Dis Treat. 2021;17:2587–98. Erratum in: Neuropsychiatr Dis Treat. 2021;17:3081–3.

[65] Sikora MLewandowska IKupc MKubalska JGraban AMarczak Łet al. Serum proteome alterations in human cystathionine β-synthase deficiency and ischemic stroke subtypes. Int J Mol Sci. 2019;20:3096.

[66] Tufekci KUVurgun UYigitaslan OKeskinoglu PYaka EKutluk Ket al. Follow-up analysis of serum TNF-related apoptosis-inducing ligand protein and mRNA expression in peripheral blood mononuclear cells from patients with ischemic stroke. Front Neurol. 2018;9:102.

[67] Genc SKizildag SGenc KAtes HAtabey N. Interferon gamma and lipopolysaccharide upregulate TNF-related apoptosis-inducing ligand expression in murine microglia. Immunol Lett. 2003;85:271–4. Erratum in: Immunol Lett. 2003;90:65.

[68] Li SYYoshida YKobayashi EKubota MMatsutani TMine Set al. Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Sci Rep. 2021;11:13450.